CA3049426A1 - Compositions and methods related to engineered fc-antigen binding domain constructs - Google Patents

Compositions and methods related to engineered fc-antigen binding domain constructs Download PDF

Info

Publication number
CA3049426A1
CA3049426A1 CA3049426A CA3049426A CA3049426A1 CA 3049426 A1 CA3049426 A1 CA 3049426A1 CA 3049426 A CA3049426 A CA 3049426A CA 3049426 A CA3049426 A CA 3049426A CA 3049426 A1 CA3049426 A1 CA 3049426A1
Authority
CA
Canada
Prior art keywords
domain
polypeptide
domain monomer
monomer
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3049426A
Other languages
English (en)
French (fr)
Inventor
Jonathan C. Lansing
Daniel ORTIZ
Carlos J. Bosques
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Momenta Pharmaceuticals Inc
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of CA3049426A1 publication Critical patent/CA3049426A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CA3049426A 2017-01-06 2018-01-05 Compositions and methods related to engineered fc-antigen binding domain constructs Abandoned CA3049426A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443523P 2017-01-06 2017-01-06
US62/443,523 2017-01-06
PCT/US2018/012689 WO2018129397A1 (en) 2017-01-06 2018-01-05 Compositions and methods related to engineered fc-antigen binding domain constructs

Publications (1)

Publication Number Publication Date
CA3049426A1 true CA3049426A1 (en) 2018-07-12

Family

ID=62791385

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3049426A Abandoned CA3049426A1 (en) 2017-01-06 2018-01-05 Compositions and methods related to engineered fc-antigen binding domain constructs

Country Status (7)

Country Link
US (1) US20200040084A1 (https=)
EP (1) EP3565595A4 (https=)
JP (1) JP2020514301A (https=)
AU (1) AU2018205272A1 (https=)
CA (1) CA3049426A1 (https=)
RU (1) RU2019124709A (https=)
WO (1) WO2018129397A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112912103B (zh) * 2018-05-21 2025-08-29 广州邦定生物技术有限公司 多价蛋白质复合物
JP2021531757A (ja) * 2018-07-11 2021-11-25 モメンタ ファーマシューティカルズ インコーポレイテッド 改変されたＦｃ−抗原結合ドメイン構築体に関する組成物および方法
WO2020014542A2 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
US20220267460A1 (en) * 2018-07-11 2022-08-25 Momenta Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
CN113382749A (zh) * 2018-07-11 2021-09-10 动量制药公司 与工程化Fc-抗原结合结构域构建体有关的组合物和方法
MX2021010039A (es) * 2019-02-26 2021-09-21 Pieris Pharmaceuticals Gmbh Novedosas proteinas de fusion especificas para cd137 y gpc3.
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
CA3155187A1 (en) * 2019-09-18 2021-03-25 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38
WO2021189006A1 (en) * 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iia variants
KR20230060546A (ko) * 2021-10-22 2023-05-04 상트네어바이오사이언스 주식회사 두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
WO2024219897A1 (ko) 2023-04-21 2024-10-24 상트네어바이오사이언스 주식회사 두 개의 fab 도메인 및 두 개의 fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
WO2024219894A1 (ko) 2023-04-21 2024-10-24 상트네어바이오사이언스 주식회사 두 개의 fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304715A1 (en) * 2006-03-03 2009-12-10 Tokyo University Of Science Modified antibodies with enhanced biological activities
US20080311034A1 (en) * 2007-04-30 2008-12-18 Anderson Glenn M Anti-Tissue Factor Antibodies and Compositions with Enhanced Effector Function
WO2012116926A1 (en) * 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
KR101632620B1 (ko) * 2011-07-27 2016-06-23 글락소 그룹 리미티드 Ｆｃ 도메인에 융합된 항­ｖｅｇｆ 단일 가변 도메인
TW201444872A (zh) * 2013-03-06 2014-12-01 Merrimack Pharmaceuticals Inc 抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體
US10858417B2 (en) * 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
JP2017518965A (ja) * 2014-05-02 2017-07-13 モメンタ ファーマシューティカルズ インコーポレイテッ エンジニアリングされたＦｃ構築物に関連する組成物および方法

Also Published As

Publication number Publication date
EP3565595A4 (en) 2021-03-17
RU2019124709A3 (https=) 2021-12-21
WO2018129397A1 (en) 2018-07-12
AU2018205272A1 (en) 2019-07-25
EP3565595A1 (en) 2019-11-13
US20200040084A1 (en) 2020-02-06
JP2020514301A (ja) 2020-05-21
RU2019124709A (ru) 2021-02-08

Similar Documents

Publication Publication Date Title
US20200040084A1 (en) Compositions and methods related to engineered fc-antigen binding domain constructs
US20220064298A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CTLA-4
US20220267460A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
US20210269546A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CD38
US20210317227A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
US20210147549A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO PD-L1
CA3105985A1 (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4
US20210284717A1 (en) Compositions and methods related to engineered fc-antigen binding domain constructs
WO2020014545A1 (en) Compositions and methods related to engineered fc-antigen binding domain constructs
AU2020351234A1 (en) Compositions and methods related to engineered Fc-antigen binding domain constructs targeted to CD38

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20240417